We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A phase 3 trial of RedHill Biopharma’s Crohn’s disease asset has met its primary endpoint. The study linked antibiotic cocktail RHB-104 to a higher rate of remission than placebo after 26 weeks, although the difference between the two arms shrunk later in